Molecular Breast Imaging Market

Global Molecular Breast Imaging Market Snapshot (2023 to 2033)

The global molecular breast imaging market was valued at USD 846.7 Million in 2022 and is expected to reach USD 1.4 Billion by 2033. The screening application with around 56.7% value share, has topped the global market within the application category in 2022 and is expected to grow at a CAGR of close to 4.7% over the forecast period (2023 to 2033).

Market Outlook-

Key Market Attributes

Market Size, 2022	USD 846.7 Million
Market Size, 2023	USD 883.4 Million
Market Size, 2033	USD 1.4 Billion
Value CAGR (2023 to 2033)	4.8%

Molecular breast imaging (MBI), also known as breasts specific gamma imaging (BSGI), is a diagnostic imaging modality using gamma cameras and radiopharmaceutical to identify breast cancer. Its uptake is influenced by factors like blood flow, mitochondrial activity, and physiologic factors.

• MBI has a high sensitivity of 89%-96.4%, comparable to Magnetic Resonance Imaging (MRI), and can detect high-risk lesions like atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) (NCBI, 2023- Study on Invasive Lobular Carcinoma).

Although not recommended for generalized screening, MBI is suitable for diagnostic evaluation, patients with contraindications to MRI, newly diagnosed breast cancer, and women with dense breast tissue.

Analysis of Historical and Future Outlooks Molecular Breast Imaging Market

The global market for molecular breast imaging was around 18.6% of the overall USD 4.55 Billion of the global breast imaging market in 2022.

Semi Annual Market Update

Particular	Value CAGR
H1	4.27% (2022 to 2032)
H2	5.24% (2022 to 2032)
H1	3.85% (2023 to 2033)
H2	5.68% (2023 to 2033)

MBI can reliably image subcentimeter cancers and produce projections similar to mammography, making it more integrated into clinical practice. There are various configurations of breast-specific gamma cameras, including single-headed and dual-headed models.

MBI involves injecting radiopharmaceutial technetium-99m sestimibi, Miraluma, into the venous system, and the patient is positioned while seated with the breast compressed between the detector and compression plate or two detectors in a dual-headed camera. The radiologist reviews initial images and can acquire additional images as needed.

Owed to the above factors, the global market is projected to grow at CAGR of 4.8% in forecasted period.

Brief Outlook on Key Opportunities for Molecular Breast Imaging Service Provider

The molecular breast imaging (MBI) market is expected to grow due to the growing prevalence of dense breast tissue within the screening population, affecting large patient pool.

• In a study published by American Association for Cancer Research - 2021, based on the Breast Imaging Reporting and Data System (BI-RADS) for breast composition classification, it was estimated that around 40 to 50% of women in the United States who have been receiving mammogram are likely to have mamographically dense breasts.

Traditional breast cancer detection methods, like mammography, are sensitivity-limited, causing false-negative results for individuals with dense breasts. MBI offers a promising solution for millions of individuals with dense breasts, offering high detection rates and negative predictive value as per Journal of Nuclear Medicine- Official Publication, Society of Nuclear Medicine 2022. It offers advantages over other supplemental screening methods like breast MRI, whole-breast ultrasound, and contrast-enhanced mammography.

With its safety, affordability, ease of access, quick imaging acquisition and interpretation times, and acceptable rates of false-positive findings, MBI is likely to witness increasing adoption in the market. Healthcare providers and patients alike are recognizing the benefits of this technology, leading to a higher demand for MBI systems and services.

The molecular breast imaging (MBI) market is poised for substantial growth due to its potential to significantly improve breast cancer detection rates while minimizing associated risks. Recent studies have demonstrated that the estimated benefit of MBI, in terms of deaths averted, far outweighs the estimated risk of lives lost, with the benefit-to-radiation risk ratio now approaching that of mammography. This critical finding instils confidence in the safety and efficacy of MBI as a powerful screening tool.

One of the key factors driving the market's expansion is the promising data from the prospective multicenter Density MATTERS trial (NCBI, 2022). This study compared MBI with tomosynthesis as a supplemental screening method for women with dense breasts. The results revealed an impressive incremental cancer detection rate of 9.3 per 1,000 screened. Such a high detection rate is a compelling indicator of MBI's superior capability to identify breast cancer, particularly in women with dense breast tissue, where traditional screening methods like mammography may have limitations.

Given these significant advancements and the robust evidence supporting MBI's benefits, the demand for molecular breast imaging technologies is expected to soar. Healthcare providers and patients alike are increasingly recognizing the value of MBI in improving early cancer detection, leading to better treatment outcomes and potentially saving lives.

As the awareness of MBI's advantages spreads, more medical facilities are likely to adopt this cutting-edge technology, fostering the growth of the MBI market and, more importantly, contributing to better breast cancer care worldwide.

Overview of Factors Restraining the Demand for the Molecular Breast Imaging

MBI may require tiled image acquisitions if the breast size exceeds the field of view, making lesions near the chest wall and axillary lymph nodes difficult to visualize. MBI should not be scheduled within 4 half-lives of other 99mTc-based studies, positron emission tomography (PET) / computerized tomography (CT), or targeted radionuclide therapies due to photon energy window overlap.

However, it has limitations such as 28 to 40 minutes of an imaging examination, higher whole-body radiation exposure variable insurance coverage, the need for nuclear medicine licensing and coordination, and lack of widespread availability.

Further, The American College of Radiology does not currently recommend MBI for breast cancer imaging as an adjunctive breast cancer screening basis breast density.

These constraints underscore the difficulties that the molecular breast imaging market is facing.

Country-wise Insights

Market Growth Outlook by Key Countries

Country	Value CAGR
United States	4.5%
Germany	5.8%
United Kingdom	5.1%
Japan	5.0%
China	5.1%
India	4.9%

United States - a Prominent Market for Molecular Breast Imaging Globally

The United States occupies 30.9% value share in 2022 globally.

The United States has large population suffering from breast cancer as well as those with dense breast tissue.

• Dense breast tissue affects 43% of the United States screening population, lowering sensitivity for breast cancer diagnosis (NCBI, 2022).

Growing efficiency of MBI backed by factors such as low false-positive rates, good recall rates, quick interpretation times, a low cost, minimal contraindications, and a strong negative predictive value has increased its demand for breast cancer screening in the United States. Thus making United States a prominent market for molecular breast imaging in North America region

• As per Journal of Nuclear Medicine- Official Publication, Society of Nuclear Medicine 2023, MBI offers 5–9 times more benefit than mammography in supplementary screening, helping 16-20 million people with thick breasts at risk of false-negative findings.

Germany - a Highly Lucrative Market for Molecular Breast Imaging

Germany occupies 23.1% value share in 2022 with Europe. Expenditure on molecular breast imaging in 2022 was USD 57.5 Million.

The current age-based mammographic breast cancer screening recommendation in Germany is for women aged 50-69, although new recommendations advise screening decisions should be based on individual risk.

• According to a Cancer prevention research (Philadelphia, Pa.) 2021 study, 10,498,000 women aged 50 to 69 are eligible for screening, with 39,000 women aged 40 to 49 also eligible. The number required to identify one breast cancer case was 282, which was the same for all 50-69 women.

Longer screening intervals may be suggested for low-risk women to minimize needless diagnostic procedures. Risk-adapted mammographic screening might help high-risk women while lowering expenses and stress on low-risk women. As a result, Germany tends to be a lucrative market for the molecular breast imaging industry.

China - a Large Market for Molecular Breast Imaging

In 2022, the China held a dominant stance in the East Asian market and contributed around USD 54.9 Million.

• According to GLOBOCAN 2020, In China, breast cancer is the most prevalent cancer among women, with 416,371 new cases and 117,174 deaths in 2020.

Chinese patients have a younger median age of onset, resulting in longer follow-up and treatment periods. This increases the disease burden for individuals and society. Chinese women undergo breast cancer screening earlier to reduce disease burden and improve prognosis.

China updates guidelines, conducts large-scale cohort studies, and standardized screenings. This will significantly increase survival and reduce mortality in the Chinese population. This makes China a large market for molecular breast imaging.

Category-wise Insights

Insight into Leading Modality Impacting Global Market Expansion

Market Growth Outlook by Key Modality

Modality	Value CAGR
Single Head Gamma Camera	5.1%
Dual Head Camera	4.6%

By modality, dual head camera covered 61.4% of global market share in 2022.

The dual-head system allows for simultaneous capture of breast images in the craniocaudal, medial, and lateral regions. The sensitivity of dual-head molecular breast imaging for tumors larger than 10 mm in diameter varies the most across blinded assessors. With the addition of the second detector head, the sensitivity for the tiniest breast cancers (diameters 5 mm) is improved. Thus, dual head camera are predicted to expand rapidly between 2023 and 2033.

Analysis of Key Application Leading the Molecular Breast Imaging Market

Market Growth Outlook by Key Applications

Application	Value CAGR
Screening	4.7%
Diagnosis	5.0%

The market value of screening application in molecular breast imaging market is USD 480.1 Million, representing for a sizable 56.7% market share in 2022.

MBI is a highly sensitive imaging technique that can detect breast cancer even in dense breast tissue. It has been shown to be more effective in detecting small tumours and lesions that may not be visible on mammogram. MBI has lower false-positive rate compared to other imaging modalities, such as MRI or ultrasound. This means that fewer women may be subjected to unnecessary follow-up tests or biopsies.

It offers a more comprehensive and accurate assessment of breast health, especially for women with dense breasts or other risk factors. It can be a valuable addition to the standard breast cancer screening protocols, improving early detection and potentially saving lives.

Overview of Key End User Benefiting the Global Market

Market Growth Outlook by Key End Users

End Users	Value CAGR
Hospital	4.3%
Diagnostic Imaging Centers	4.8%
Breast Cancer Care	5.8%

The hospitals have a considerable presence in the molecular breast imaging market, accounting for 41.4% of end users in 2022, and exhibiting a CAGR of 4.3% over the forecast period.

Hospitals have access to state-of-art imaging equipment, including specialized molecular breast imaging machines. This ensures that patients receive the most accurate and reliable imaging results for early detection and diagnosis of breast cancer. Hospitals often conduct clinical trials and research studies related to breast cancers and imaging technologies. It provides a holistic approach to breast cancer care, making it the preferred choice for end users in molecular breast imaging.

Competitive Landscape

Innovations and acquisitions among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten molecular breast imaging. Collaboration in research, development, and commercialization leads to market expansion and the creation of new applications. Numerous large firms compete in the field of molecular breast imaging. Among the well-known players in this field are-

• In March 2023, Philips introduces the Zenition 10 image-guided therapy system, a low-cost, high-quality system using flat panel detector technology for improved patient outcomes in surgical care, trauma, and orthopaedics.
• In July 2021, Fujifilm Healthcare Europe acquired Hitachi Diagnostic Imaging for 179 billion yen in March 2021, offering comprehensive clinical solutions in CT, MRI, ultrasound, x-ray, women's health, AI, PACS, and IVD.

Similarly, recent developments related to the companies active within the molecular breast imaging market have been tracked by the team at Future Market Insights, which are available in the full report.

Related Market Growth Outlook Scenario

Particulars	Value CAGR
Breast Cancer Drugs Market	1.1%
Breast Biopsy Devices Market	5.4%
Breast Lesion Localization Devices Market	5.4%

Report Scope as Per Molecular Breast Imaging Industry Analysis

Attribute	Details
Forecast Period	2023 to 2033
Historical Data Available for	2017 to 2022
Market Analysis	USD Million for Value, Units for Volume
Key Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA)
Key Countries Covered	United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Russia, Nordics, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Vietnam Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa.
Key Market Segments Covered	Modality, Application, End User, and Region
Key Companies Profiled	Koninklijke Philips N.V. (Netherlands); Hitachi Ltd. (Japan); Siemens Healthcare GmbH (Germany); CANON MEDICAL SYSTEMS CORPORATION (Japan); General Electric (US); Aspect Imaging Ltd (Israel); Bruker (US),; Aurora Health Care (US); FONAR Corp. (US); ESAOTE SPA (Italy); Neusoft Corporation (China); TOSHIBA CORPORATION (Japan); Sanrad Medical Systems Private Limited (India); FUJIFILM Holdings Corporation (Japan); ONEX Corporation (Canada); Hologic, Inc. (US); Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China); Imaging Diagnostic Systems, Inc. (US); Agfa-Gevaert Group (Belgium); Koning Health (China)
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing	Available upon Request

Key Market Segments Covered in the Molecular Breast Imaging Industry Research

By Modality:

• Single Head Gamma Camera
• Dual Head Camera

By Application:

• Screening
• Diagnosis

By End User:

• Hospital
• Diagnostic Imaging Centers
• Breast Cancer Care

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Frequently Asked Questions

How much is the global market worth in 2022?

The global market is worth USD 846.7 Million in 2022.

What is the global market estimated to reach by 2023?

The global market estimates for 2023 is around USD 883.4 Million.

What is the sales forecast for the global market through 2033?

The global market is expected to reach USD 1.4 Billion by the end of 2033, with a sales revenue expected to register 4.8% CAGR.

What was the last five years’ growth rate for molecular breast imaging market?

The global market grew at a CAGR of 3.9% between 2017 and 2022.

What is the United States market outlook for the molecular breast imaging?

The United States dominated the global market contributing around USD 262.0 Million in the year 2022.

How much is the Germany’s market worth in 2022?

Germany holds nearly 6.8% market share in the global market in 2022.

What is the outlook of the China market?

China accounted for a market value share of around 6.5% in 2022, in the global market.